PMID- 33410093
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210619
IS  - 2509-4254 (Electronic)
IS  - 2509-4262 (Print)
IS  - 2509-4262 (Linking)
VI  - 5
IP  - 2
DP  - 2021 Jun
TI  - Understanding Patients' Willingness to Pay for Biphasic Insulin Aspart 30/70 in a 
      Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market.
PG  - 261-273
LID - 10.1007/s41669-020-00246-3 [doi]
AB  - OBJECTIVE: Our objective was to investigate willingness to pay (WTP) for biphasic 
      insulin aspart 30/70 (BIAsp 30) in patients with type 2 diabetes mellitus (T2DM) 
      in India. METHODS: A multicenter, prospective, non-interventional, preference 
      study was conducted that assessed WTP for BIAsp 30 in an insulin pen (FlexPen((R)) 
      or Penfill((R)) device) in patients in India with T2DM previously treated with 
      biphasic human insulin (BHI) in vials and believed to be able to pay for 
      treatment. The primary endpoint was the proportion of patients willing to 
      continue to pay for BIAsp 30 after 12 weeks' treatment. Secondary endpoints 
      included the change from baseline in treatment and device satisfaction and 
      patient preferences for treatment attributes as assessed by a nested 
      discrete-choice experiment. RESULTS: Overall, 54.9% (n = 277/505) of participants 
      were male; the mean age was 56.4 years; diabetes duration was 10.9 years; 63.8% 
      had a body mass index >/= 25 kg/m(2); > 75% had an annual household income > 
      150,000 Indian rupees (INR). After 12 weeks' treatment, 96.4% of patients were 
      willing to pay for BIAsp 30. Mean treatment and device satisfaction significantly 
      improved from baseline (p < 0.0001). Patients were willing to pay INR3576 (95% 
      confidence interval [CI] 2755-4398) for improved glycemic control, INR688 (95% CI 
      383-994) for a device upgrade (vial/syringe to an insulin pen), or INR327 (95% CI 
      95-560) to avoid major hypoglycemia. Patients would need to be compensated INR44 
      (95% CI 56-32) per minor hypoglycemic event. CONCLUSIONS: In India, patients with 
      T2DM previously treated with BHI were willing to pay for BIAsp 30 in an insulin 
      pen. Furthermore, treatment and device satisfaction improved after this 
      therapeutic switch. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03374774.
FAU - Murthy, Sreenivasa
AU  - Murthy S
AD  - LifeCare Hospital and Research Centre, Bangalore, Karnataka, India. 
      drsreenivasamurthy@gmail.com.
FAU - Aneja, Pankaj
AU  - Aneja P
AD  - Max Super Speciality Hospital, Shalimar Bagh, New Delhi, India.
FAU - Asirvatham, Arthur Joseph
AU  - Asirvatham AJ
AD  - Arthur Asirvatham Hospital, Madurai, Tamil Nadu, India.
FAU - Husemoen, Lise Lotte N
AU  - Husemoen LLN
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Rhee, Nicolai A
AU  - Rhee NA
AD  - Novo Nordisk Health Care AG, Zurich, Switzerland.
FAU - Kesavadev, Jothydev
AU  - Kesavadev J
AD  - Jothydev's Diabetes Research Center, Trivandrum, Kerala, India.
LA  - eng
SI  - ClinicalTrials.gov/NCT03374774
PT  - Journal Article
DEP - 20210106
PL  - Switzerland
TA  - Pharmacoecon Open
JT  - PharmacoEconomics - open
JID - 101700780
PMC - PMC8160041
COIS- NAR and LLNH are employees of the sponsor (at Novo Nordisk Health Care AG) and 
      own shares in the company. JK is in the Speaker's bureau for Novo Nordisk. SM, 
      PA, and AJA have no conflicts of interest that are directly relevant to the 
      content of this article.
EDAT- 2021/01/08 06:00
MHDA- 2021/01/08 06:01
PMCR- 2021/01/06
CRDT- 2021/01/07 06:14
PHST- 2020/12/10 00:00 [accepted]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/08 06:01 [medline]
PHST- 2021/01/07 06:14 [entrez]
PHST- 2021/01/06 00:00 [pmc-release]
AID - 10.1007/s41669-020-00246-3 [pii]
AID - 246 [pii]
AID - 10.1007/s41669-020-00246-3 [doi]
PST - ppublish
SO  - Pharmacoecon Open. 2021 Jun;5(2):261-273. doi: 10.1007/s41669-020-00246-3. Epub 
      2021 Jan 6.